FDA Clears New Version of AI Segmentation Software for Brain MRI
Offering rapid automated segmentation of brain structures, the ClearPoint 2.2 software reportedly enhances visualization for a variety of targeted, MRI-guided procedures.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence (AI)-enabled ClearPoint 2.2 software, which provides automated segmentation of brain structures from magnetic resonance imaging (MRI) scans.
ClearPoint Neuro, the manufacturer of the software, said it provides rapid segmentation that facilitates a variety of targeted, MRI-guided procedures ranging from deep brain stimulation to laser ablation.
Here one can see a comparison of the ClearPoint Maestro Brain Model (a) and the ClearPoint 2.2 software (b), which includes segmentation of subnuclei. (Images courtesy of NeuroImage.)
The ClearPoint 2.2 software also includes the Maestro Brain Model, which was recently validated in a study published in NeuroImage. In a quantitative reproducibility analysis, researchers found the combination of the shape-constrained deformable brain model and voxel-wise tissue segmentation was superior to manual expert segmentation.
“The ClearPoint system can now offer fast, peri-procedural segmentation of the cortical structures of the brain to identify both targets and safety zones for cell and gene therapy delivery, laser ablation, biopsy and deep brain stimulation,” noted Joe Burnett, the president and CEO of ClearPoint Neuro.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
